Prospective validation of a model-informed precision dosing tool for vancomycin treatment in neonates

Antimicrob Agents Chemother. 2024 Apr 5:e0159123. doi: 10.1128/aac.01591-23. Online ahead of print.ABSTRACTWe recruited 48 neonates (50 vancomycin treatment episodes) in a prospective study to validate a model-informed precision dosing (MIPD) software. The initial vancomycin dose was based on a population pharmacokinetic model and adjusted every 36-48 h. Compared with a historical control group of 53 neonates (65 episodes), the achievement of a target trough concentration of 10-15 mg/L improved from 37% in the study to 62% in the MIPD group (P = 0.01), with no difference in side effects.PMID:38578080 | DOI:10.1128/aac.01591-23
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Source Type: research